BTG Share News (BTG)

Tuesday broker round-up UPDATE

African Minerals: Canaccord Genuity lowers target price from 20p to 15p with a hold recommendation. Aggreko: Exane initiates with a target price of 1500p and an underperform rating. Amec: Liberum Capital cuts target price from 1035p to 908p staying with its sell recommendation. Antofagasta: Canacc

UK BROKER RATINGS: Merrill Lynch Cuts Schroders To Underperform

UK MIDDAY BRIEFING: Tesco Bolsters Board With Experienced Retailers

TOP NEWS: German Factory Orders, Eurozone Investor Sentiment Decline

London open: Banks, supermarkets give FTSE 100 a lift

Decent gains from banking and supermarket stocks gave the FTSE 100 a boost on Monday morning as the UK's benchmark index continues to recover after hitting a 10-month low last week. The Footsie was trading 0.4% higher at 6,554 early on, rising for the second straight day after falling to 6,446.39 la

BTG expects strong momentum to continue in second half

BTG has given a bullish outlook for its annual performance after a strong start to the year, with the specialist healthcare company entering the second half "confident of continuing this strong momentum". In spite of adverse currency exchange movements, the group expects revenues to be around the to

UK MORNING BRIEFING: Tesco Leads Opening Gains As It Bolsters Board

BTG Strengthens Full-Year Revenue Expectations On Good First Half

UK BROKER RATINGS: Goldman Sachs Raises Debenhams To Neutral

DIRECTOR DEALINGS: BTG CEO Exercises Options

UK MIDDAY BRIEFING: CSR Leaps On Approach, Xaar Plummets

UK WINNERS & LOSERS: CSR Shares Rise By A Third As It Considers Sale

UPDATED TOP NEWS: Ukrainian President Accuses Russia Of Invasion

TOP NEWS: CSR Rejects US Takeover Offer As Xaar Lowers Forecast

BTG granted approval in China for liver cancer treatment

Specialist healthcare company BTG and its partner SciClone Pharmaceuticals have received approval from the China Food and Drug Administration for the registration of its DC Bead treatment for a type of malignant liver tumour. Following the approval, the partners have started planning the treatment